Sign Up to like & get
recommendations!
2
Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1043680
Abstract: Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders. Here, we characterized KZR-616 in vitro and in vivo using multiplexed cytokine analysis, lymphocyte activation and differentiation, and differential…
read more here.
Keywords:
616 attenuates;
mice via;
kzr 616;
zetomipzomib kzr ... See more keywords